Medinews· @Medinews_ · X·· 2 days agoScore70
Body
Studio di Fase III #NATALEE, presentati ad #ESMO26 i risultati dell’analisi di follow-up a 6 anni.
Ne parliamo qui: https://www.medinews.it/comunicati/ribociclib-dimostra-un-beneficio-in-termini-di-sopravvivenza-globale-nella-piu-ampia-popolazione-di-pazienti-con-tumore-della-mammella-hr-her2%e2%88%92-in-fase-iniziale/
@myESMO
42 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Medinews · x.com